官方服务：
资源简介：
FXa Inhibition Ameliorates Pulmonary Hypertension
应用场景：
创建时间：
2025-04-03
相关数据集
Chronic Pulmonary Hypertension Treatment Market
Global Chronic Pulmonary Hypertension Treatment Market Report 2024 comes with the extensive industry analysis of development components, patterns, flows and sizes. The report also calculates present a
IMR REPORTS40
Predictors of Operability in Children with Severe Pediatric Pulmonary Hypertension Associated With Congenital Heart Disease
This was a retrospective cohort study of 59 consecutive children (aged 2–18 years) with a diagnosis of severe PAH-CHD secondary to a simple shunt defect, who underwent surgical repair for CHD, with or
NIAID Data Ecosystem30
中国结缔组织病相关肺动脉高压诊治专家共识
肺动脉高压是结缔组织病(CTD)的严重并发症之一，起病隐匿，早期诊断困难，治疗效果不佳，亦是当前 CTD 患者死亡的重要因素之一。中国医师协会风湿免疫科医师分会风湿病相关肺 血管/间质病学组、国家风湿病数据中心、国家皮肤与免疫疾病临床医学研究中心联合，针对临床实践中一线医师关注的 9 个临床问题提出了较为详细的推荐意见，旨在提高 CTD 相关肺动脉高压诊疗的 科学性与规范性，改善患者预后，提高生活
国家人口健康科学数据中心10
Pressure ratio of target lesion before and after BPA.
Pressure ratio of target lesion before and after BPA.
NIAID Data Ecosystem40
Pulmonary vasodilators and oxygen therapy at baseline, at the pulmonary hypertension relief phase, and at 6 months post-final balloon pulmonary angioplasty.
Pulmonary vasodilators and oxygen therapy at baseline, at the pulmonary hypertension relief phase, and at 6 months post-final balloon pulmonary angioplasty.
NIAID Data Ecosystem10
